SLC5A2 and acute kidney injury: A meta-analysis of 55 randomized clinical trials, performed in 2013, demonstrated that canagliflozin and dapagliflozin use was associated with an increased risk of AKI compared to use of non-SGLT-2 inhibitor antihyperglycemic agents [12].